Stockscreener 앱 받기
40.00
0.32%
-0.13
시간 외 거래:
40.00
전일 마감가:
$40.13
열려 있는:
$39.33
하루 거래량:
711.17K
Relative Volume:
0.99
시가총액:
$2.32B
수익:
$32.87M
순이익/손실:
$674.31M
주가수익비율:
3.5211
EPS:
11.36
순현금흐름:
$-330.11M
1주 성능:
-7.90%
1개월 성능:
-1.23%
6개월 성능:
+32.89%
1년 성능:
-10.77%
1일 변동 폭
$38.90
$40.32
1주일 범위
$38.90
$44.10
52주 변동 폭
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
명칭
Agios Pharmaceuticals Inc
전화
617-649-8600
주소
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
40.00 | 2.34B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-27 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 개시 | Piper Sandler | Overweight |
| 2022-11-17 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-03-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-02-15 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 개시 | Leerink Partners | Mkt Perform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-04-11 | 재확인 | Credit Suisse | Outperform |
| 2018-02-15 | 재확인 | Needham | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-10 | 재확인 | Needham | Buy |
| 2017-08-08 | 재확인 | SunTrust | Buy |
| 2017-08-02 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-01-17 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 개시 | Needham | Buy |
| 2016-06-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 재확인 | SunTrust | Buy |
모두보기
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
What earnings revisions data tells us about Agios Pharmaceuticals Inc.Earnings Risk Summary & Reliable Price Breakout Signals - newser.com
Is Agios Pharmaceuticals Inc. (8AP) stock a top dividend aristocrat candidate2025 Price Targets & Low Risk Entry Point Tips - newser.com
Will Agios Pharmaceuticals Inc. stock see PE expansionJuly 2025 Short Interest & Risk Controlled Swing Alerts - newser.com
How supply chain issues affect Agios Pharmaceuticals Inc. stockQuarterly Trade Summary & Verified Short-Term Plans - newser.com
How Agios Pharmaceuticals Inc. (8AP) stock correlates with oil marketsMarket Risk Report & Smart Investment Allocation Tips - newser.com
Will Agios Pharmaceuticals Inc. benefit from macro trendsMarket Sentiment Summary & High Conviction Buy Zone Picks - newser.com
Q3 2025 HighlightsAgios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones - Seeking Alpha
Institutional scanner results for Agios Pharmaceuticals Inc.Market Movement Recap & Daily Oversold Stock Bounce Ideas - newser.com
Agios (AGIO) Unveils Promising Mitapivat Data at ASH 2025 - GuruFocus
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition - The Manila Times
What data driven models say about Agios Pharmaceuticals Inc.’s futureQuarterly Trade Summary & Daily Entry Point Alerts - newser.com
Agios (Nasdaq: AGIO) shows mitapivat data: 77.8% alpha-thal response; 30.5-week mean - Stock Titan
Can Agios Pharmaceuticals Inc. stock deliver sustainable ROEShare Buyback & AI Powered Market Entry Ideas - newser.com
Is Agios Pharmaceuticals Inc. building a consolidation basePortfolio Risk Report & AI Driven Stock Movement Reports - newser.com
What is HC Wainwright's Estimate for AGIO FY2025 Earnings? - MarketBeat
Can Agios Pharmaceuticals Inc. stock reach $100 price targetWeekly Trade Review & Reliable Trade Execution Plans - newser.com
Is it time to cut losses on Agios Pharmaceuticals Inc.Inflation Watch & Breakout Confirmation Alerts - newser.com
Is Agios Pharmaceuticals Inc. stock supported by strong cash flows2025 Technical Patterns & Real-Time Buy Signal Notifications - newser.com
What drives Agios Pharmaceuticals Inc stock priceMarket Capitalization Trends & High Return Capital Strategies - earlytimes.in
Is Agios Pharmaceuticals Inc. (8AP) stock among top earnings playsMarket Volume Summary & Safe Capital Growth Trade Ideas - newser.com
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Savvy Advisors Inc. Takes Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Published on: 2025-11-02 02:45:06 - newser.com
Candlestick signals on Agios Pharmaceuticals Inc. stock todayQuarterly Market Summary & Reliable Price Action Trade Plans - newser.com
Agios Pharmaceuticals Q3 2025 Earnings Preview - MSN
Agios outlines Q4 2025 PYRUKYND milestones and anticipates U.S. thalassemia approval amid global expansion - MSN
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2025 Earnings Call Transcript - Insider Monkey
RBC Capital Keeps Their Buy Rating on Agios Pharma (AGIO) - The Globe and Mail
Published on: 2025-11-01 04:26:21 - newser.com
Agios Pharmaceuticals Inc (AGIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):